Balaji Gandhi Sells 5,827 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 5,827 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $27.31, for a total transaction of $159,135.37. Following the transaction, the chief financial officer now owns 141,846 shares of the company’s stock, valued at approximately $3,873,814.26. This represents a 3.95 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The stock was sold at an average price of $26.98, for a total transaction of $22,555.28.
• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total value of $85,018.95.

Phreesia Trading Down 0.2 %

Shares of NYSE PHR traded down $0.06 during midday trading on Wednesday, hitting $27.29. The company’s stock had a trading volume of 389,445 shares, compared to its average volume of 386,096. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.16. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.59 billion, a P/E ratio of -18.56 and a beta of 0.94. The business’s 50 day moving average is $23.77 and its two-hundred day moving average is $22.94.

Phreesia (NYSE:PHR) last released its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business’s revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.58) earnings per share. As a group, equities research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Institutional Investors Weigh In On Phreesia

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC grew its stake in Phreesia by 2,179.7% in the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after acquiring an additional 1,395 shares in the last quarter. Lombard Odier Asset Management USA Corp purchased a new stake in shares of Phreesia in the second quarter valued at approximately $202,000. Point72 DIFC Ltd bought a new position in Phreesia in the second quarter worth approximately $209,000. XTX Topco Ltd purchased a new position in Phreesia during the 3rd quarter worth $247,000. Finally, Hsbc Holdings PLC bought a new stake in Phreesia during the 2nd quarter valued at $301,000. Institutional investors own 92.10% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PHR shares. Needham & Company LLC restated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research report on Friday, January 10th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Robert W. Baird decreased their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. KeyCorp lifted their price target on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Finally, JMP Securities restated a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research report on Tuesday, December 10th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.